# Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

> **NCT00466531** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00466531
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2007-03-21
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00466531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00466531, "Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00466531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*